Loading stock…

Eli Lilly and Company (LLY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Eli Lilly and Company

LLYMarket cap $1.1TPrice $1188.7

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures prescription drugs for diabetes, cancer, and obesity, with blockbuster treatments like Ozempic rival Mounjaro. Controls nearly 25% of the global insulin market and pioneered mass insulin production.

In Bastion Portfolios?

52W Return+49%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+32%10

Revenue Forecast

Rev CAGR (1y)+36%9

Rev CAGR (3y)+21%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+1+60%9

EPS Growth Y+2+29%8

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin50%10

Net Income Margin34%9

Free Cash Flow Margin23%8

Debt

Net Debt/EBITDA1.16

Efficiency

ROE102%10

ROA22%10

Earnings Stability88

GEAR+VERY STRONG98

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)282

P/E Ratio (Forward 3y)222

P/BV31.31

EV Multiples

EV/EBITDA Fwd252

EV/EBIT Fwd263

Yield

Free Cash Flow Yield1.7%4

Dividend Yield0.6%2

Momentum

Short term

1 month return+6%9

3 month return-2%6

YTD return+11%7

Mid term

Price vs 52wHigh92%9

1 year return+41%9

Long term

3 year return+115%8

5 year return+432%10

Risk Shield

Price Risk

Beta0.58

Volatility34%6

Free Cash Flow

Free Cash Flow Margin23%8

Free Cash Flow Yield1.7%4

Quality

ROCE51%10

Earnings Stability88

Net Debt/EBITDA1.16

02Growth

Is it actually growing, and how fast?

LLYEli Lilly and

Revenue FY25$65.2B

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+32%10

Revenue, next 1Y+36%9

Revenue, next 3Y, CAGR+21%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+60%9

EPS growth, FY27E+29%8

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 32%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 21%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 29%/yr vs revenue 21%/yr), so margins should widen.

WATCH

Revenue grew 32%/yr over the last 3 years; forecasts see it cooling to 21%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-2%6

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+41%9

3-year return+115%8

5-year return+432%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +115% over three years and +432% over five, ahead of 80% of the market.

It's up 41% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%) and so far this year (+11%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Eli Lilly. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LLYEli Lilly and

Revenue FY25$65.2B

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+32%10

Revenue, next 1Y+36%9

Revenue, next 3Y, CAGR+21%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+60%9

EPS growth, FY27E+29%8

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 32%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 21%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 29%/yr vs revenue 21%/yr), so margins should widen.

WATCH

Revenue grew 32%/yr over the last 3 years; forecasts see it cooling to 21%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG91 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-2%6

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+41%9

3-year return+115%8

5-year return+432%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +115% over three years and +432% over five, ahead of 80% of the market.

It's up 41% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%) and so far this year (+11%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Eli Lilly. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community